Last reviewed · How we verify

Fidia Farmaceutici s.p.a. — Portfolio Competitive Intelligence Brief

Fidia Farmaceutici s.p.a. pipeline: 3 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Liposom Forte Liposom Forte marketed
Itami Itami marketed Other
Tricortin 1000 Tricortin 1000 marketed ACTH analog Melanocortin-2 receptor (MC2R) Endocrinology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Attune Health Research, Inc. · 1 shared drug class
  2. NYU Langone Health · 1 shared drug class
  3. University of Colorado, Denver · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fidia Farmaceutici s.p.a.:

Cite this brief

Drug Landscape (2026). Fidia Farmaceutici s.p.a. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fidia-farmaceutici-s-p-a. Accessed 2026-05-17.

Related